## Musculoskeletal services in Aneurin Bevan Local Health Board

"There are over 200 different types of arthritis and musculoskeletal conditions"

Musculoskeletal conditions are the most common type of self-reported illness, and account for almost 20% of all GP consultations in the UK<sup>1,2</sup>

"In Wales £90 million is spent each year on incapacity benefits to individuals suffering with back pain"


Approximately 27,000 people living with arthritis in the UK are under the age of 25<sup>2</sup>

Welsh Assembly Government, Service Development and Commissioning Directives: Arthritis and Chronic Musculoskeletal Conditions, 2007

<sup>2</sup>Arthritis Care, *FAQs*, 2011, accessed via:

nttp://www.artnritiscare.org.uk/A

<sup>3</sup>Aneurin Bevan Local Health Board, *FOI response*, 2012



Expenditure on musculoskeletal conditions at Aneurin Beyan<sup>3</sup>:

2009/10 £64,223,000 2010/11 £65,275,000

There have been nine rheumatologists at Aneurin Bevan Local Health Board over the last three years.

All newly diagnosed patients are given Arthritis UK information packs and booklets. They are also encouraged to join patient support groups through the websites of the individual organisations.

Includes musculoskeletal
conditions within definition of
long-term conditions

×

Identified all long-term conditions patients



Audit of outcomes for patients with musculoskeletal conditions



A list of all clinical guidelines and protocols for musculoskeletal conditions



Received information about the Service Development and Commissioning Directives for arthritis and chronic musculoskeletal conditions



Works with voluntary and community organisations to support patients with musculoskeletal problems



## SERVICES AVAILABLE FOR PEOPLE WITH

## MUSCULOSKELETAL CONDITIONS:

- Pain management service
- Physiotherapy service
- Inflammatory arthritis service
- Community falls service
- Education for GPs about how to manage patients with suspected rheumatoid arthritis
- Information for patients on self care

The drafting and production of this document has been funded by Roche Products Ltd and Chugai Pharma UK Ltd.
Full editorial control rests with ARMA.

January 2013 RCUKCOMM00153